Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer remains one of the leading causes of death among Hispanics/Latinos in the U.S., accounting for approximately 17% of deaths. At the same time, federal support for health equity and cancer disparities research is facing unprecedented cuts—making community-driven leadership more critical than ever.
Cancer affects Latino men and women differently, requiring targeted approaches. Among Latinas, breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer death, while cervical cancer continues to pose a serious and largely preventable threat.
For Latino men, the challenges are equally urgent. Lung cancer remains the leading cause of cancer death, and Latino men are more likely to be diagnosed with prostate, colorectal, liver, and testicular cancers—often at later stages.
Our mission. The Latino Cancer Institute works to reduce the burden of cancer in Latino communities by convening expertise, amplifying community-informed research, and advocating for equitable cancer care. As public funding becomes more uncertain, philanthropic support helps ensure Latino communities are not left out of cancer research, policy discussions, or solutions. Learn more about our work.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute convenes leading experts, advocates, and community voices to examine critical cancer issues affecting Latino communities and to surface actionable insights. Recordings from TLCI’s recent Forums are now available—free to watch—covering cancer risks, disparities, and lived experiences across Latino women, men, children, and families. Watch Forum videos.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
Women who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer’s disease in their brains, according to a large study of more than 21,000 participants. Hormone therapy use was linked to 39% lower odds of a dementia diagnosis and 35% lower odds of Alzheimer’s-related brain changes at autopsy, including amyloid plaques and tau tangles. Biomarker tests also suggested less amyloid buildup among hormone therapy users.
A large study of more than 5,500 adults over 50 found a striking combination of risk factors: abdominal obesity paired with vitamin D deficiency was linked to a 123% higher risk of death over six years. Each condition was associated with increased risk on its own, but together they appeared to create a dangerous feedback loop, with belly fat reducing the amount of vitamin D available in the bloodstream while low vitamin D may worsen inflammation and other health problems.
Researchers have found a striking new way to potentially eliminate HIV soon after infection using a one-time combination of three therapies. In newborn nonhuman primates treated within three days of exposure, the regimen—standard antiretroviral drugs, broadly neutralizing antibodies, and the experimental antibody leronlimab—completely cleared the virus, even though none of the treatments could do so alone.
UCLA researchers have created a blood test that can scan DNA signals for multiple cancers, liver diseases, and signs of organ damage—and even indicate where trouble may be developing. Early results suggest the inexpensive approach could bring medicine closer to a single blood test capable of catching a wide range of diseases before they become harder to treat.
A protein that evolved long before the human circulatory system may help unlock stronger cancer treatments. When C3 is produced inside tumors, it blocks immune-suppressing cells and gives immunotherapy a better chance to work. Researchers were even able to recreate this effect in resistant tumors, significantly improving survival in mice.
Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients.
Sept. 18, 25 
